Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.65 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | TDO2 | P48775 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893366 | 0.89 | ESR1 (0.52) | ACHEALDH1A1ESR1PDCD1ESR2 | |
| Ammonia Solution, Strong SCHEMBL7995946 | 0.87 | ESR1 (0.50) | ACHEALDH1A1ESR1PDCD1ESR2 | |
| SCHEMBL146509 | 0.87 | ESR1 (0.55) | ACHETDP1ALDH1A1LMNAESR1 | |
| Ammonia Solution, Strong SCHEMBL7995783 | 0.84 | ESR1 (0.52) | ACHETDP1ALDH1A1LMNAESR1 | |
| SCHEMBL18293317 | 0.82 | CYP17A1 (0.47) | ACHEESR1PDCD1ESR2CD274 | |
| SCHEMBL20868149 | 0.82 | ACHE (0.68) | ACHENFE2L2TDP1ALDH1A1LMNA | |
| SCHEMBL12789806 | 0.81 | ACHE (0.59) | ACHENFE2L2TDP1ALDH1A1LMNA | |
| SCHEMBL12689 | 0.81 | — | — | |
| SCHEMBL7025938 | 0.81 | — | — | |
| SCHEMBL19194402 | 0.81 | DAO (0.41) | ACHENFE2L2TDP1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-18 | — | — | US | disclosed |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-02-21 | — | — | US | disclosed |
| EP-3324975-B1 | COMPOSITION COMPRISING A THERAPEUTIC AGENT AND A RESPIRATORY STIMULANT AND METHODS FOR THE USE THEREOF | HSU JOHN (US) | 2022-05-18 | — | — | EP | disclosed |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2021-03-04 | — | — | US | disclosed |
| US-9079834-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-07-14 | — | — | US | disclosed |
| US-20140018325-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-01-16 | — | — | US | disclosed |
| US-8088346-B2 | Alkene hydrofunctionalization reactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088346-B2 | Alkene hydrofunctionalization reactions | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090069580-A1 | Alkene Hydrofunctionalization Reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
| US-20090069580-A1 | Alkene Hydrofunctionalization Reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018325-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, FURIN | ACHE 230/4885NFE2L2 4697/4885TDP1 1016/4885 |
| US-11584747-B2 | Substituted pyridopyrimidinonyl compounds useful as T cell activators | DGKZ, DGKA, DGKG | ACHE 3397/4885NFE2L2 4411/4885TDP1 1200/4885 |
| US-20210061802-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACHE 3397/4885NFE2L2 4411/4885TDP1 1200/4885 |
| US-20090069580-A1 | Alkene Hydrofunctionalization Reactions | ADH1A, ADH1C, ADH5 | ACHE 2281/4885NFE2L2 111/4885TDP1 4135/4885 |
| US-20230151007-A1 | SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | ACHE 3586/4885NFE2L2 4032/4885TDP1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.